Overcoming Failure as a Recent Pharmacy Graduate
Pharmacy Times
NOVEMBER 12, 2024
Failing is not final, and it does not define what kind of pharmacist or resident a student can be.
Tue.Nov 12, 2024
145 
STAT+: How Pfizer used wearables to tap into the promise of an experimental drug
STAT
NOVEMBER 12, 2024
Pfizer’s promising research on a treatment for a dangerous cancer-related condition is also helping prove out the value of wearables in clinical trials. In September, the pharma giant reported results showing that an experimental antibody could positively impact people with cachexia, a complication sometimes called “wasting syndrome” that can cause people with cancer to lose weight and make it harder for them to tolerate treatments.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Varying Messaging Strategies Increases Likelihood of Vaccination Against HPV
Pharmacy Times
NOVEMBER 12, 2024
There were differences in the variables that influenced vaccination decision making for adults aged 18 to 26 years and for parents making the decision to vaccinate their child
The recovery community says it offers refuge from opioid addiction. But it’s still hostile to lifesaving addiction medications
STAT
NOVEMBER 12, 2024
The last time Mark Palinski went to a Narcotics Anonymous meeting, he was asked to leave and never come back. He stills remembers the argument: All he had done was advocate for the use of the “gold standard” treatment opioid addiction, a common medication called buprenorphine. To Palinski, buprenorphine is a godsend.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacists Combat Flu Misinformation and Expand Vaccine Access
Pharmacy Times
NOVEMBER 12, 2024
Kristi Veis discusses the importance of flu vaccinations and the role of pharmacists in administering them.
Cardinal Health inks two deals worth $3.9B to expand diabetes, gastroenterology businesses
Fierce Healthcare
NOVEMBER 12, 2024
Cardinal Health plans to buy two companies that will expand its diabetes and gastroenterology businesses as part of an overall strategy to grow its footprint in specialty medicine. | Cardinal Health plans to buy two companies that will expand its diabetes and gastroenterology businesses as part of an overall strategy to grow its footprint in specialty medicine.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
OpenAI isn’t built for health care. So why is its tech already in hospitals, pharma, and cancer care?
STAT
NOVEMBER 12, 2024
The company behind ChatGPT didn’t set out to tackle health care.
New Model Can Assess Blast Phase Progression Risk in Myeloproliferative Neoplasms
Pharmacy Times
NOVEMBER 12, 2024
According to the study, 20% of patients with myeloproliferative neoplasms progress to blast phase.
STAT+: RNA startup Orna Therapeutics cuts more jobs
STAT
NOVEMBER 12, 2024
Biotech startup Orna Therapeutics has cut more jobs in its second round of layoffs in the last year, STAT has learned. Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic, planning to create a new, more durable type of RNA-based medicines. It launched in 2021 and quickly garnered attention from Gilead subsidiary Kite Pharma, Bristol Myers Squibb, Novartis, and Merck.
Building Resilience: Opportunities for US Pharma to Strengthen Public Health in Africa Amid Changing Aid Policies
Pharmacy Times
NOVEMBER 12, 2024
Africa’s rapidly growing population, expected to reach 2.5 billion by 2050, means an increasing demand for health care and medications.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Bayer's rising prostate cancer star Nubeqa crosses blockbuster barrier as Xarelto continues downward descent
Fierce Pharma
NOVEMBER 12, 2024
Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns” in the road ahead, Bayer is confident that the course it’s laid out th | As Xarelto generics continue to eat away at sales, Bayer's Nubeqa and Kerendia are picking up the slack while Regeneron-partnered Eylea makes for a solid base.
Proposed Biosimilar to Ocrelizumab Shows Comparability With Reference Product
Pharmacy Times
NOVEMBER 12, 2024
Ocrelizumab (Ocrevus; Genentech) is used for the management and treatment of multiple sclerosis.
Pfizer explores sale of hospital drugs unit amid activist investor’s call for accountability: Reuters
Fierce Pharma
NOVEMBER 12, 2024
After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to slim down by divesting its hospital drugs unit,
Bispecific Antibody Receives FDA Orphan Drug Designation for the Treatment of Multiple Myeloma
Pharmacy Times
NOVEMBER 12, 2024
LBL-034 could be best in class in treating individuals with multiple myeloma.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
How DSCSA Serves as the Drug Supply Chain’s Lead Investigator | ASPL 2024
Drug Topics
NOVEMBER 12, 2024
Pharmacy law experts detailed the Drug Supply Chain Security Act, highlighting the role each entity within the supply chain plays in ensuring the safety and authenticity of US prescription drugs.
DOJ sues to block UnitedHealth's $3.3B acquisition of Amedisys
Fierce Healthcare
NOVEMBER 12, 2024
The Department of Justice filed suit on Tuesday to block UnitedHealth's $3.3 billion acquisition of home health company Amedisys, arguing that the deal would stifle competition in this space. | The Department of Justice filed suit on Tuesday to block UnitedHealth's $3.3 billion acquisition of home health company Amedisys, arguing that the deal would stifle competition in this space.
Daiichi and AZ pull Dato-DXd filing with FDA and try again
pharmaphorum
NOVEMBER 12, 2024
Daiichi Sankyo and AstraZeneca give up on their NSCLC application for Dato-DXd, and refile seeking a narrower label
STAT+: AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
STAT
NOVEMBER 12, 2024
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of lung cancer, a step that will delay the drug’s arrival on the market and that will add to questions about how widely it could be used. The medicine, datopotamab deruxtecan, or Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies have been pouring investments into.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Pharmaceutical Technology
NOVEMBER 12, 2024
The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.
NHS England relaunches anti-smoking pill programme
pharmaphorum
NOVEMBER 12, 2024
'Game-changer' daily pill to quit smoking returns to NHS after three-year absence after a deal between Teva and NHS England
Greater Depression Severity Linked with Increased Diabetes Risk
Drug Topics
NOVEMBER 12, 2024
A recent study found that with greater depression severity, metabolic and clinical characteristics such as HbA1c, fasting blood glucose, and triglyceride levels increased.
Neurogene shares fall on Rett syndrome gene therapy data
pharmaphorum
NOVEMBER 12, 2024
Neurogene says Rett syndrome gene therapy improves clinical symptoms, but a serious adverse event causes shares to fall
Copayment Burden Affects Medication Adherence in Chronic Conditions
Drug Topics
NOVEMBER 12, 2024
High copayments can be a structural barrier to medication therapy adherence.
Growing threat of AMR: UN calls for urgent global action
pharmaphorum
NOVEMBER 12, 2024
The United Nations is calling for urgent global action to address the growing threat of antimicrobial resistance (AMR). Learn more about this pressing issue and what steps can be taken to combat it effectively.
FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy
Drug Topics
NOVEMBER 12, 2024
The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.
Could this oatmeal drink help you lose weight?
The Checkup by Singlecare
NOVEMBER 12, 2024
First came Ozempic , then “Oatzempic,” the viral social media trend that has people drinking their oats in the name of weight loss. It’s no surprise that given constipation and other side effects sometimes associated with GLP-1 drugs like Wegovy and Mounjaro , people have turned to alternative options. But does blending your oats actually work? Despite its catchy name and online buzz, “the ‘Oatzempic’ drink is not a medication or an equivalent substitute for Ozempic or other GLP-1 agonists, and
Q&A: Insights on HIV Care, Pharmacists’ Expanding Role
Drug Topics
NOVEMBER 12, 2024
Cassandra Esperant, PharmD, AAHIVP, leverages her expertise as a clinical pharmacist to advocate for the well-being of individuals with HIV.
Abbisko’s pimicotinib hits primary endpoint in phase 3 TGCT trial
Outsourcing Pharma
NOVEMBER 12, 2024
Abbiskoâs small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial giant cell tumor (TGCT), taking the asset a step further to the market in China and elsewhere.
The Nuances of Marijuana’s Potential Rescheduling | ASPL 2024
Drug Topics
NOVEMBER 12, 2024
FDA experts gathered to discuss the DEA’s rescheduling of marijuana and how it will impact the pharmaceutical supply chain.
Merck drug for rare tumour hits phase 3 target
pharmaphorum
NOVEMBER 12, 2024
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.The German group said the CSF-1R inhibitor given as a once-daily, oral dose hit its primary endpoint in the MANEUVER study, achieving an objective response rate (ORR) at week 25 of 54% compared to 3.2% for a matched placebo in patients with TGCT, a rare disease affecting the joints and tendons.
STAT+: Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more
STAT
NOVEMBER 12, 2024
Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search of creatures to annoy. As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own hectic agendas. So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list.
Abbisko’s pimicotinib hits primary endpoint in phase 3 TGCT trial
Outsourcing Pharma
NOVEMBER 12, 2024
Abbisko’s small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial giant cell tumor (TGCT), taking the asset a step further to the market in China and elsewhere.
With high hopes for the economy, AstraZeneca adds $2B to US investment in manufacturing, R&D
Fierce Pharma
NOVEMBER 12, 2024
Citing a rosy view of the U.S. | AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5 billion. The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way.
Let's personalize your content